Cingulate (CING) Competitors

Cingulate has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amarin had 3 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Amarin and 0 mentions for Cingulate. Amarin's average media sentiment score of 0.86 beat Cingulate's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Amarin presently has a consensus price target of $13.00, indicating a potential upside of 8.42%. Cingulate has a consensus price target of $27.00, indicating a potential upside of 453.28%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Amarin.

Cingulate has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cingulate's return on equity.

Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market.

22.3% of Amarin shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cingulate has a consensus price target of $27.00, indicating a potential upside of 453.28%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Aurora Cannabis.

Cingulate has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Cingulate's return on equity.

Cingulate has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

In the previous week, Aurora Cannabis had 22 more articles in the media than Cingulate. MarketBeat recorded 22 mentions for Aurora Cannabis and 0 mentions for Cingulate. Aurora Cannabis' average media sentiment score of 0.17 beat Cingulate's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cingulate has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Palisade Bio has higher revenue and earnings than Cingulate. Palisade Bio is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Palisade Bio's return on equity of -33.47% beat Cingulate's return on equity.

In the previous week, Palisade Bio had 3 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Palisade Bio and 0 mentions for Cingulate. Palisade Bio's average media sentiment score of 0.34 beat Cingulate's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Cingulate currently has a consensus price target of $27.00, suggesting a potential upside of 453.28%. Palisade Bio has a consensus price target of $9.83, suggesting a potential upside of 578.16%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Cingulate.

Cingulate has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Cingulate presently has a consensus price target of $27.00, indicating a potential upside of 453.28%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 1.09%. Given Cingulate's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cingulate is more favorable than Lifecore Biomedical.

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cingulate has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 6 more articles in the media than Cingulate. MarketBeat recorded 6 mentions for Lifecore Biomedical and 0 mentions for Cingulate. Cingulate's average media sentiment score of 0.00 beat Lifecore Biomedical's score of -0.08 indicating that Cingulate is being referred to more favorably in the media.

Cingulate has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Cingulate's return on equity.